Recalled Medicines & supplements – Current GIS Alerts 2026
Found 713 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Lidocaine hydrochloride monohydrate, 100 mg/100 mg, 1 g pack
In one pack of the pharmaceutical raw material Lidocaine hydrochloride monohydrate a different active substance (hydrocortisone) was found, creating a risk of preparing a medicine with a qualitative composition not compliant with the prescription. Potential effects: lack of treatment efficacy, unintended steroid effects, therapy complications.
Seronil
The non-compliance in the level of N-nitroso fluoxetine impurity indicates a loss of the medicine’s quality, and the established acceptance criterion was exceeded, so a risk to human health cannot be excluded. Potential effects: increased risk of toxic effects, complications and altered treatment efficacy.
KIMMTRAK
The identified non‑compliance in the “strength” parameter affects product quality and may impact the effectiveness and safety of its use. A risk to human health cannot be excluded if this batch remains on the market. Potential effects: reduced treatment efficacy or adverse effects.
Magne B6
The failure to meet quality requirements consists in exceeding the lower specification limit for pyridoxine hydrochloride (vitamin B6) release in stability testing under the registered storage conditions. Potential effects: possible reduced treatment effectiveness and lack of the expected supplementation effect.
Elenium
The identified non-compliance in the dissolution rate of the active substance affects the quality of the medicine, which may impact its efficacy and safety; a risk to human health cannot be excluded. Potential effects: lack of treatment efficacy, disease worsening, adverse effects related to incorrect dosing.
Elenium
A non-compliance of the active substance dissolution parameter was found in stability studies, meaning reduced and delayed drug release and uncertainty regarding the efficacy and safety of the tablets throughout their shelf life. Potential effects: lack of treatment efficacy, disease complications.
Clatra
Contamination with particles visible to the naked eye was found in Clatra eye drops; the particles correspond to precipitation of the active substance, with a tendency for this phenomenon to increase as the medicine ages. Potential effects: eye irritation, discomfort, possible reduction of treatment efficacy.
Dexapini
Sediment in the form of crystals was found at the bottom of the syrup bottle, not compliant with the quality specification. Failure to determine the cause of crystallization and the risk of disturbed antimicrobial protection and microbiological purity prevent ruling out a risk to patient health. Potential effects: infections, lack of treatment efficacy, health complications.
Dexapini
A quality defect was found consisting of sediment in the form of crystals at the bottom of the bottle and a real suspicion of loss of syrup quality, related to potential disruption of antimicrobial protection and microbiological purity of the medicine, which may pose a health risk. Potential effects: infections, lack of treatment efficacy, health complications.
Korzeń Kozłka
Non‑compliance with quality requirements was found in the form of too low content of sesquiterpenic acids, which may reduce the effectiveness of the medicinal product. Potential effects: lack of or reduced therapeutic effect.
Korzeń Kozłka
A non‑compliance with quality requirements was found in the parameter of sesquiterpene acid content, which may affect the effectiveness of the product, even though no direct threat to the patient’s life or health was stated. Potential effects: lack of therapeutic efficacy.
Sunitinib Vipharm
The product does not meet quality requirements due to a negative test result for the “appearance” parameter – altered appearance of the capsule filling compared with the approved specification. Potential effects: possible non‑compliance of therapy with documentation and uncertainty regarding treatment quality.
Sunitinib Vipharm
The product does not meet its specified quality requirements due to a negative test result for the appearance parameter; the changed appearance of the capsule filling has not yet been approved in the quality specification. Potential effects: possible concern about medicine quality and a potential risk of dose non-uniformity.
Sunitinib Vipharm
The product does not meet quality requirements due to a negative test result for the appearance parameter; the altered capsule filling appearance does not match the currently registered quality specification. Potential effects: possible deviations in dosing and therapeutic effectiveness.
Inuprin Forte
The risk of impaired antimicrobial protection and microbiological purity of the medicine due to crystallization of sucrose in the syrup cannot be excluded. Potential effects: possible infections, reduced treatment efficacy, complications in patients.
Varilrix
The decision indicates the occurrence of a threat to public health and a real risk to patients’ health and life, considered by the authority as obvious. Potential effects: serious adverse reactions, risk to patients’ health and life.
Vitamina C Synteza
The identified non-compliance in the form of brown spots and discoloration on the capsule surface may affect the safety of medicinal product use; a risk to human health and life cannot be excluded. Potential effects: possible health risk, potential complications related to inadequate medicine quality.
Vitamina C Synteza
The identified non‑conformity in the form of brown spots and discolorations on the capsule surface may affect the safety of use of the medicinal product. Therefore, a risk to human health and life cannot be excluded. Potential effects: possible risk to health and complications related to improper drug action.
VBLAAST 10
The presence of particles visible to the naked eye of unidentified origin was found in the solution for injection, which creates a real danger of such particles entering the patient’s bloodstream and may lead to unpredictable, negative health effects. Potential effects: embolic complications, vascular damage, severe systemic reactions, life-threatening conditions.
VBLAAST 10
Visible particles of unidentified origin were found in the solution for injection, which creates a real risk of such particles entering the patient’s bloodstream and may lead to unpredictable, negative health effects. Potential effects: embolic complications, tissue damage, severe systemic complications.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.